May 1, 2001Annals of Pharmacotherapy
New Recommendations from the 1999 American College of Cardiology/American Heart Association Acute Myocardial Infarction Guidelines
Key result
The 1999 ACC/AHA guidelines for acute myocardial infarction updated recommendations to emphasize fibrin-specific thrombolytics, GP IIb/IIIa inhibitors in NSTEMI, and lower unfractionated heparin doses.
Population
Patients with acute myocardial infarction (AMI)
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Documents evolution of AMI pharmacotherapy recommendations; leaves open translation to contemporary reperfusion strategies.
Structured PICO
P
Population
Patients with acute myocardial infarction (AMI)
I
Intervention
Updated drug therapy recommendations (fibrin-specific thrombolytics, GP IIb/IIIa inhibitors, clopidogrel, unfractionated heparin, beta-blockers) and primary percutaneous coronary intervention
The 1999 ACC/AHA AMI guidelines introduced significant updates to pharmacological management, including the preference for fibrin-specific thrombolytics, clopidogrel, and lower-dose unfractionated heparin.
Cite This Study
Spinler et al. (2001) conducted a review in Acute myocardial infarction (AMI). Guideline-directed medical therapy and primary angioplasty was evaluated. The 1999 ACC/AHA guidelines for acute myocardial infarction updated recommendations to emphasize fibrin-specific thrombolytics, GP IIb/IIIa inhibitors in NSTEMI, and lower unfractionated heparin doses.